A Study of LY3314814 in Participants With Liver Impairment



Status:Withdrawn
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 85
Updated:6/30/2018
Start Date:June 2018
End Date:December 2018

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment

The purpose of the study is to determine whether LY3314814 can be safely prescribed in
participants with liver impairment without a dose adjustment. Participants will be on study
for 11 days with follow-up about 7 days afterward.


Inclusion Criteria:

- Have a Body Mass Index (BMI) of 18 to 40 kilogram per meter square (kg/m²), inclusive, at
the time of screening

Exclusion Criteria:

- Have a history of or current significant ophthalmic disease, particularly any eye
problem involving the retina

- Have moderate or severe vitiligo or any other clinically significant disorder of skin
or hair pigmentation

- Have acute unstable neuropsychiatric disease

- Have active or uncontrolled neurologic disease, or clinically significant head injury
We found this trial at
4
sites
New Orleans Cntr for Clin Res
Knoxville, Tennessee 37920
Principal Investigator: William B Smith
Phone: 865-305-9100
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Orlando Clinical Research Center
5055 South Orange Ave Orlando FL 32909
Orlando, Florida 32806
407-240-7878
Principal Investigator: T C Marbury
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Clinical Pharmacology of Miami
Miami, Florida 33014
Principal Investigator: K C Lasseter
Phone: 305-817-2900
?
mi
from
Miami, FL
Click here to add this to my saved trials
Orange County Research Center
Tustin, California
Principal Investigator: J M Neutel
Phone: 714-550-9990
?
mi
from
Tustin, CA
Click here to add this to my saved trials